Audrey’s Selected Meeting List for December 2008

***************************************************** BayBio “Run Wild for a Child” Run, Walk, Volunteer, Sunday, Nov. 30, 2008

On Sunday November 30th, Thanksgiving Weekend, what better way to burn off the turkey and kick off the Holiday Season than a beautiful run or walk in Golden Gate Park. 'Run Wild for A Child' features a 5K or 10K run/walk and a 5K costume contest in which you're encouraged to run as a favorite childhood toy. 'Run Wild Like a Child' offers great prizes for the top 10 costumes, like Southwest Airlines tickets and New Balance Shoes. All registered runners/walkers will receive an official 100% cotton long sleeve t-shirt with the event logo and a goodie bag.

Or you can lend a hand, volunteers are needed on race day to help make the run safe and fun for everyone. As a thank you for your time volunteers will receive an official 100% cotton long sleeve event crew t-shirt with the event logo and a goodie bag.

And, you'll kick-start the Holiday Season with the right spirit when you bring an unwrapped toy or two for the San Francisco Firefighter's Toy Program.

When: Sunday, November 30 Where: Golden Gate Park Attire: Running gear Cost: 5K or 10K (Adult Fee - Race Only) $28.00 with BayBio discount code

provided below

How to regsiter and get the BayBio discount: go to http://www.rhodyco.com/runwild.html click on 'REGISTER ONLINE' in the registration process you will be asked:

'Do you have a 'Discount Code'? check 'yes' and when asked, supply the following:

Club Name: BayBioClub Code: 0213

To volunteer: email nancy@rhodyco.com or call (415) 759-2

***************************************************** Bio2Device Group, Tuesday Morning, Dec. 2, 2008

Topic: "Design Control—Good Engineering, Not Just Paperwork”Speaker: Tom Shoup, Ph.D.Date and Time: Tuesday, Dec. 2, 2008, 8:30 – 10:30 amLocation: Room 510, 505 W. Olive, Sunnyvale, CA (end of one-story office building next to Sunnyvale Public Library)Cost: Free

1 5/25/2023

Topic DescriptionThe successful development of products, especially medical devices, requires that the design be controlled to assure product safety and that the device can fulfill its intended use.  Too often, companies view design control as nuisance paperwork to satisfy regulatory requirements and fail to capitalize on the good engineering it embodies.  The 9 elements of design control contribute practical engineering value by making design objectives clearer, products more testable, and better able to satisfy customer requirements—thereby shortening the path to product and business success.  Speaker BioTom Shoup, Ph.D., has more than 20 years of experience in medical device development for class II and class III devices.  Past employers include Hewlett-Packard and Siemens, where he held senior R&D management positions with responsibility for product development, project management, and day-today compliance with design control.

***************************************************** PWHA, Wednesday Evening, Dec. 3, 2008

Event: PWHA's Annual Holiday Charity EventWednesday December 3, 20085:30-8:00 PMAbbott Vascular3200 Lakeside DriveSanta Clara, CA 95054

Cost: Advance Registration fees (up to December 1):$25 Members$30 Non-members Register at

https://guest.cvent.com/EVENTS/Register/IdentityConfirmation.aspx?e=d6c9547d-953b-4064-9728-49774e20865a  At the door:$30 Members$35 Non-members 

Event DescriptionCatch up with old friends and meet new onesWhile supporting a worthy cause at Beverages and hors d'oeuvres will be served, and the event will feature a raffle of gently used, celebrity donated designer handbags, from  This Old Bag .   All Proceeds will benefit the Breast Cancer Emergency Fund.

2 5/25/2023

    About the Breast Cancer Emergency Fund:Breast Cancer Emergency Fund (BCEF) provides short-term emergency financial assistance to low-income San Franciscans battling breast cancer. To learn more:http://www.breastcanceremergencyfund.org/***************************************************** Palo Alto AWIS , Monday Evening, Dec. 8, 2008

Topic:  December Chapter Meeting: Networking and Raffle! Date and Time: Monday, December 8, 2008, 7:00 pm - 9:00 pm Location: Palo Alto Research Center (PARC) Directions to PARC. For details and to register, go to http://www.pa-awis.org/ Topic DescriptionPlease join us for a fun night of meeting new people and polishing your skills. Do youknow what you would say if you had 2 minutes with the hiring manager at the company of your dreams? 2 minutes with the recruiter? 2 minutes with a VP? We’ll also practice our elevator pitches and review interview skills. Don’t forget to bring plenty of business cards! We will be selling Raffle tickets for "Curl up with a Book Basket"; the winner will be announced at our December event. All proceedings from the raffle will support our scholarship program for women majoring in science at local community colleges.

*****************************************************

Bio2Device Group, Tuesday Evening, Dec. 9, 2008

Topic: “Using the ‘Voice of Patient’ (or doctor, nurse or caretaker) to turn Well- Engineered Devices into Well-Designed Products and Experiences”Speaker: Eric Freitag, Director, Engineering Services of Smart Design and Lead of their Healthcare InitiativeDate and Time: Tuesday evening, Dec. 9, 2008, 6-9 pm Schedule

6:00 to 6:45 pm --Join us for a light dinner and networking6:45 pm to 8:15 --Meeting will begin, speaker’s presentation, followed by open networking9:00 pm -- Out the door.

Location: TIPS PC Group, 1000 Elwell Court, Suite 150, Palo Alto, California 94303-4318, 650.293.3350NO DAYTIME MEETINGREGISTRATION REQUIRED Pre-registration thru Acteva is RequiredRegister here for the December 9, 2008 meeting with Eric Freitag.<http://www.acteva.com/booking.cfm?bevaid=171327>

3 5/25/2023

Must pre-register through Acteva or pay at a B2DG morning meeting See details at www.bio2devicegroup.orgCost: Cost for pizza or salad only. Register at <http://www.acteva.com/booking.cfm?bevaid=171327>

Topic DescriptionOver the last decade, technological innovations in the healthcare field have outpaced the industry’s appreciation for the needs of the medical consumer: including health practitioners, caregivers and patients.  Recently, Smart Design conducted a study to identify the critical drivers behind the development of successful medical diagnostic equipment, drug-delivery devices, and hospital instrumentation, and rediscovered the importance of good design in an otherwise engineering dominated industry. 

As quality healthcare moves out of the hospital and into the home, products and services need to become more user-friendly by addressing consumers’ emotional needs.  Similarly, as financial challenges and capacity limitations continue to squeeze hospitals, health professionals need ergonomically correct surgical instruments to allow them to do their jobs safely and accurately.

Smart Design is a product design and development firm that specializes in user centered research activities to help companies translate their technological advantage into useful benefits for the end user.

Speaker BioEric Freitag is the Director of Engineering Services for Smart Design and leads their Healthcare Initiative.  Eric heads a team of Design Engineers who work closely with Industrial Designers, Interaction Designers, and Communication Designers to deliver multi-disciplinary solutions for clients. Eric has more than 10 years of experiences developing successful medical devices from early concept, through proof of principal, design development, verification and validation testing, FDA approval, production ramp-up and launch.  Eric has led programs for small medical start-ups such as Helicor and Z-Kat, consumer packaged goods companies such as Johnson & Johnson and Vicks, as well as larger medical device manufacturers such as Becton Dickenson and Covidien (formerly Kendall-Tyco).

Eric has a BSE in Mechanical Engineering, a BS in Economics and a MSE in Architectural Engineering from U.C. Berkeley, where he earned a patent on a thermostat that used real time weather data to predict the next day’s temperature to pre-cool or pre-heat buildings.  He also owned and operated the Bison Brewing Company in Berkeley, California (just in case you wanted to know).

Sponsor and Hosted by: TIPS Group <http://www.tipsgroup.com/>

Directions: New venue at TIPS' Conference Center 1000 Elwell Court,Palo Alto. Exit 101 and head North on San Antonio Road. Turn left ontoEast Bayshore Road. The TIPS office is on the corner of East Bayshoreand Elwell. A large parking area is at the rear of the building (either

4 5/25/2023

turn right at the FEDEX box off of Bayshore, or turn right onto Elwelland then right into the first driveway). See map and photo of the siteat http://biodevicegroup.org/addl_directions.html

*****************************************************

East Bay AWIS, Tuesday Evening, Dec. 9, 2008

EVENT: DECEMBER NETWORKING SOCIAL

Date and Time: December 9th, 2008,6:30 pm - 8:00 pmLocation: Jupiter  (upstairs seating),2181 Shattuck Ave.,Berkeley, CA 94704Directions: http://www.jupiterbeer.com/jupiter/info.htm Please join us at Berkeley's popular beer garden Jupiter for an informal gathering of AWIS members and friends!Cost: free (cash bar)

*****************************************************

BayBio Healthcare Conference, Wednesday Morning, Dec. 10, 2008Topic: Healthcare Innovation in the 21st Century: HHS’ Dynamic Role in the Biomedical and Device Development Process Date and Time: December 10, 9:00am - 11:00amLocation:: Byers Auditorium in Genentech Hall at UCSF Mission Bay, San Francisco, CA Directions.

Parking: Paid parking is available on campus Attire: Business Attire Suggested

Cost: Complimentary

AgendaWelcoming RemarksRegis B. Kelly, Ph.D.Director, The California Institute for Quantitative Biosciences (qb3)

Opening Remarks and Introduction of Deputy Secretary Tevi TroyMatthew M. GardnerPresident and CEO, BayBio

Promoting and Facilitating Innovation: HHS’ Dynamic RoleTevi D. Troy, Ph.D.Deputy Secretary, U.S. Department of Health and Human Services

NIH: Investing in InnovationAlan Guttmacher, M.D.Acting Director, National Human Genome Research Institute National Institutes of Health

5 5/25/2023

FDA: Paving the Pathway for InnovationFrank Torti, M.D., M.P.H.Principal Deputy Commissioner and first Chief Scientist Food and Drug Administration

CMS: Funding the Innovators of Today and TomorrowHerb KuhnDeputy Administrator and Acting Director, Center for Medicaid and State OperationsCenters for Medicare and Medicaid Services (Tentative)

AHRQ: Helping Organizations Innovate and Adopt New IdeasJean Slutsky, M.S.P.H.Director, Center for Outcomes Evidence (Tentative

Registrations:Please contact Public Affairs Manager Kathryn Bailey to register.

Pre-registered attendees will receive an immediate receipt/confirmation after submission. Please print this receipt/confirmation and bring it with you to receive your conference credentials. Photo ID (driver's license or passport) will be required at check-in.

Please mail your event-related questions to: kbailey@baybio.org or you can contact us via phone: 650-871-7101.

Topic Descriptionwill address opportunities and challenges in the development and regulation of new life sciences and medical device technologies. As HHS works to create an environment that promotes innovation, it must also maintain a rigorous approval process that ensures the safety of the American people.

At the conference, attendees will interact with a panel of representatives including Department of Health and Human Services (HHS) Deputy Secretary Tevi Troy, Ph.D., as well as senior officials from National Institutes of Health (NIH), the Food and Drug Administration (FDA), the Centers for Medicare and Medicaid Services (CMS), and the Agency for Healthcare Research and Quality (AHRQ). Together, they will highlight the work taking place in and between their agencies to facilitate the development of medical technologies. Attendees will have the opportunity to exchange ideas with representatives of the agencies.

*****************************************************

TIE, Wednesday Lunchtime, Dec. 10, 2008

6 5/25/2023

Topic: Biotechnology in the New World – Silicon ValleySpeaker: Fred FrankVice Chairman & Director, Barclays CapitalDate and Time: Wednesday, Dec. 10, 2008, 11:00 am to 1:00 pm12/10/2008 11:00 AM Registration & Networking 12/10/2008 11:30 AM Lunch 12/10/2008 12:00 PM Presentation 12/10/2008 01:00 PM Close

Location: Latham & Watkins LLP, 140 Scott Drive, Menlo Park, CA 94025Cost: Members $30 online; Nonmembers $50 online Registration and Cancellation PolicyRegistration: Online Registration closes at 12:00 Noon a day before the event. Cancellation: All Registration Fees are Non-Refundable and No Credit is offered for cancellations.Register at https://s08.123signup.com/servlet/SignUp?PG=17291182300&P=17291191157920000

Speaker BioFred Frank is a luminary figure in the biotechnology industry and has been a leader in financing of the industry for many decades.  Fred began his career on Wall Street in 1958 and he continues to be a warm and wise friend, and mentor to companies and individuals in this industry around the world.  Fred has a deep and unique perspective on where the biotechnology industry has been and where it is headed. We are honored to be able to share his wisdom and insights about our industry as we face a complex new political and economic order nationally and globally.

***************************************************** Bioscience Business Development: Building Value, UCSC Extension in Silicon Valley, CA, Dec. 11-12, 2008

This intensive 2-day course provides an understanding of the critical roles that business development and licensing play in product commercialization and building a successful life science company. The instructors and expert guest speakers offer insight into the importance of strategic deals in building value. They discuss how to select and target potential partners; assess risks and current trends; determine value and when to deal; and maintain patent integrity worldwide. Finally, the instructors examine the deal-execution process, including negotiating terms, reaching agreement and developing the contract provisions. Students receive complimentary information on research sources and instructor guidance in preparing a business plan or opportunity assessment as term project.

Typically, students receive complimentary access to specific subscription databases as well. We anticipate access to Deloitte Recap’s Recap Basic and Biocentury once again for use in researching term papers.

Fee: $770 (Early enrollment at $693 through Nov. 27)

7 5/25/2023

To enroll visit ucsc-extension.edu/biobizdev; for questions, call 408.861.3860.

Instructors:

Audrey Erbes, Ph.D., is a marketing professional with more than 25 years of managerial experience in marketing and business development in the biotech and pharmaceutical industries. She was Executive VP and cofounder of Kowa Research Institute, a biopharmaceutical licensing and investment subsidiary of Kowa Company Ltd., Japan. Previously, she held management positions at Syntex Corp. in market research, product management, strategic marketing and planning, and business development in the U.S. and abroad, with a special emphasis on Europe and Asia/Pacific/Canada. Topic: "Business Development in the Bioscience Industry"

Gilbert R. Mintz, Ph.D., is president of GRM Associates, a biotechnology consulting firm with expertise in business development, licensing and strategic planning. With more than 20 years in the biotechnology industry, Dr. Mintz has held corporate management and executive-level business development positions at Genelabs Technologies, Anergen (Corixa), and Cygnus. He has executed technology-platform, corporate and academic collaborations and in/out licensing of late-stage products for partnerships in the U.S., Europe and Japan for such companies as Affymetrix, Aclara and Biota Inc. Topic: "Working Your Way Through the Bioscience Licensing Process: Licensing - The Process and Transaction"

Guest Speakers:Ginger Dreger, J.D., M.S., partner in Goodwin Proctor's Business Law Department and member of its Technology Companies and Intellectual Property Groups in its Palo Altooffice. Prior to joining Goodwin Procter, Ginger headed the biotechnology patent prosecution group in the Silicon Valleyoffice of Heller Ehrman.Topic: "Biotech IP Life Cycle Planning: U.S. and International Patent Issues"

Harold (Hal) Etterman, M.B.A., has over 25 years of experience in Finance, Operations and Information Technology, including over ten years serving as a CFO, COO and interim CEO. Hal supports early-stage technology businesses in formulating business strategies, venture funding and the development of strategic alliances. Topic:  "Financial Planning and Funding for a Bioscience Venture: New, Emerging and Growing Entities"

Carolyn Feamster, M.B.A., a business strategy and analysis consultant, has over 25 years of experience in the pharmaceutical and biotech arenas including therapeutics, diagnostics and drug delivery systems. She has broad expertise across numerous therapeutic areas and has held positions at Syntex, ALZA, Corixa Corporation, and Clearview Projects, where she was most recently vice president of business strategy and analysis. Topic: "Preparing for and Planning Deals for Maximum Strategic Impact"

8 5/25/2023

Thomas L. Gutshall, chairman as well as co-founder of Cepheid in 1996, was the company's first CEO. He also served as president and COO for CV Therapeutics from 1994 to 1996. Previously, he was the executive vice president for Syntex Corporation and a member of its pharmaceutical executive committee. Topic: "Cepheid: Business Model, Strategy, Plan and Implementation"

Michael G. McCully, M.S. as a Director at Recombinant Capital (Recap), consults on deal structuring and valuation for Recap Consulting clients and focuses on top-level analyses of business development activity in the biotech and pharmaceutical industry with top tier pharmaceutical firms, investment concerns, and over thirty biotech companies, ranging from early stage platform companies to late stage drug developers. Prior to Recap, Mike worked with Burrill & Company evaluating investment opportunities for the firm's venture funds and developing strategies for investments in the diagnostic space. Topic: "Biotech Business Development: Where Do We Go From Here"

Herwig von Morze, Ph.D., is an international patent consultant with 27 years of corporate patent experience in Europe and the United States. He spent 8 years (1995-2003) at Heller Ehrman, where he assisted clients in designing the most effective international patent strategy. He has extensive experience in international patent strategy, prosecution, appeal, opposition and patent term extension practice and international patent litigation. He established his own international patent practice in 2004. Topic: "Biotech IP Life Cycle Planning: U.S. and International Patent Issues”*****************************************************

BayBioNEST Technology Showcase, Thursday Evening, Dec. 11, 2008Program: Showcase of Bio-X at Standford UniversityDate and Time: December 11, 2008, 5:30pm - 8:30pm Location: Clark Center, 318 Campus Drive, Stanford Directions Click here Attire: Business Attire Suggested Cost: Advance - $20.00; At the Door - $30.00Register at http://www.acteva.com/booking.cfm?bevaid=171072Map located on http://biox.stanford.edu/clark/operations_map.html

DescriptionJoin BayBioNEST for the last of this year’s technology showcases. This event serves to introduce the life sciences community to the new wave of research that will shape the future of the industry. Bio X is at the forefront of a bold new undertaking that seeks to meet pressing medical and scientific challenges by fostering an interdisciplinary life sciences program. Don’t miss this opportunity to get a sneak peak at early science from a world class research institute and to connect with or develop relationships with Stanford research faculty and life scientists, financiers and industry executives.***************************************************** San Jose Biocenter, Thursday Afternoon, Dec. 11, 2008 

9 5/25/2023

Topic: BioCenter Annual Trends in Financing & Holiday Celebration:Will it be a toast to our future or to our demise?”Lead Facilitator: Scott M. Iyama, Corporate Lawyer, Emerging Companies Group Member, Orrick, Herrington & Sutcliffe LLPPanelists include:

Samuel D. Colella , Co-Founder and Managing Director, Versant VenturesEllen Koskinas, Partner, InterWest Partners LLC: a successful Venture Capitalist with outstanding board member experience, and who led - prior to InterWest - Guidant's acquisition of CardioThoracic Systems.

Ted Driscoll , Venture Partner, Claremont Creek Ventures Ellen Koskinas, Partner, InterWest Partners LLC

Date and Time: Thursday, December 11, 2008 | 3pm-6:30pm Location: ABD Insurance-a Wells Fargo Company, 305 Walnut Street, Redwood City, CA 95063This event is typically sold out, therefore please register early to secure your spot!• Panel + Networking Reception:     ° Regular Price: $60 before or on Dec. 5 | $70 on-site*     ° Partners' Network: $40 before or on Dec. 5 | $50 on-site*     ° BioCenter Members: Free (Please RSVP to Lauren Wakefield directly)• Networking Reception only: $30 before or on Dec. 5 | NO on-site registrations!*For on-site registration (if space allows): please bring CASH or CHECK!Topic Description“Black October hit the biotech industry hard” according to Steve Burrill’s most recent market assessment, but Silicon Valley Business Journal reports the “biotech sector edging out software as the number one industry last quarter-with the life sciences sector (biotechnology and medical devices combined) seeing a 10% increase in VC investing with $2.2 billion going into 207 deals.”

Join investors who are leading these deals to debate and discuss current market trends and what we can expect for 2009. Conflicting reports of impending doom or optimistic forecasts for the future of life sciences; we will get the answers. Speakers Bios

A highly respected venture capitalist recognized for his leadership in life sciences investing, Sam Colella co-founded Versant Ventures with six other managing directors in 1999. Over the course of his career, Mr. Colella has acquired more than 20 years of successful operating experience in the high technology industry and more than 25 years of investing experience in the healthcare sector. Prior to founding Versant, Mr. Colella managed one of the first life science-focused investing groups in the industry as a general partner with Institutional Venture Partners (IVP). Previously, he was president of a New York Stock Exchange company and held a variety of functional positions in a broad array of diverse businesses, including president of Spectra-Physics, the world's leading laser supplier, and senior manager of the Technical Products Division of Corning Glass. Having managed investments concentrated in medical devices, biotechnology and health care technology companies, Mr. Colella is credited with an extensive list of successful

10 5/25/2023

public life science companies, including Alexza Pharmaceuticals, Argonaut Technologies, Arthrocare, Athena Neurosciences, Aviron, CV Therapeutics, Endosonics, Genomic Health Inc., IVAC Holdings, Jazz Pharmaceuticals, Onyx Pharmaceuticals, Pharmacopeia, Symyx Technologies, Thermage, Tularik and Vivus. He is currently a director of Alavita, Alexza Pharmaceuticals, EuroVentures, Flexion, Genomic Health Inc., and Jazz Pharmaceuticals, Veracyte, and he is Chairman of Fluidigm, Inc. Mr. Colella’s professional affiliations include terms of service as an officer in the National Venture Capital Association, the Western Association of Venture Capitalists, and American Entrepreneurs for Economic Growth and Chairman of the Stanford Council on Interdisciplinary Biosciences. Mr. Colella has a B.S. degree in Business and Engineering from the University of Pittsburgh and an M.B.A. degree from Stanford University.

Ellen Koskinas focuses on life sciences investing, with an emphasis on medical devices. She is a board member of Applied Spine Technologies, Apsara Medical, CardioMind, EnteroMedics and Neuronetics. She has also been an active observer on the boards of Epicor (acquired by St. Jude Medical), NeuroPace and Paracor Medical. Prior to InterWest, Koskinas held a number of key roles in marketing and business development at Guidant Corporation, where she built a new business in minimally invasive cardiac surgery and then led Guidant's acquisition of CardioThoracic Systems. Koskinas has also served as an Engagement Manager for McKinsey & Company, managing projects for a broad range of pharmaceutical, healthcare delivery and medical device clients. At the outset of her career, she worked in corporate finance at Morgan Stanley in New York and London. Koskinas received a B.A. in economics with honors from Harvard College and received a M.B.A. from the Stanford Graduate School of Business.

Ted Driscoll is a Venture Partner at Claremont Creek Ventures and a Special Limited Partner at Novus Ventures. Over the past two decades, Ted helped found five successful companies in imaging-related markets. He was founder and CEO of Be Here Technologies, a pioneer in Internet, Broadcast and Videoconferencing technologies. He served as a Division President and CTO of Diasonics, with responsibility for its MRI, ultrasound, digital X-ray, lithotripsy and acoustic ablation technology areas. He had earlier directed the technology team that developed the first commercial MRI scanners and numerous advance in MR imaging. Previously, he was Vice President of Engineering and R&D of Identix, now a world leader in fingerprint and face recognition, and Director of R&D at International Imaging Systems, an early pioneer in remote sensing. His research and patents in ultrasound therapy and acoustic hemostasis also led to the founding of another company, Therus, now partnered with Boston Scientific. Ted earned a PhD from Stanford University in Digital Imaging, Masters degrees from Harvard University in Computer Graphics and Remote Sensing, and a Bachelor's degree from the University of Pennsylvania. Ted holds 40+ granted U.S. and foreign patents in image-related fields, with approximately 30 additional pending applications. Scott Iyama, a corporate attorney in Orrick's Silicon Valley office, is a member of the Emerging Companies Group, which advises emerging companies and venture capital firms. Mr. Iyama's practice focuses on the representation of emerging growth life science

11 5/25/2023

and high tech companies, as well as public offerings, private venture financings, and technology transactions. A representative list of Mr. Iyama's clients include CellPoint Dialogistic, Facebook, Greenplum, Laserscope, Micrus Endovascular and SquareOne. Mr. Iyama has also represented Benchmark Capital, De Novo Ventures, Kleiner Perkins Caufield & Byers, Maveron, Montreux Equity Partners, Telegraph Hill Partners in various investments. Prior to receiving his J.D. from Stanford Law School, Mr. Iyama received a M.S. and B.S in Biochemistry/Cell Biology from the University of California, San Diego. Mr. Iyama also performed extensive research at Genentech, Inc. and the NASA/Ames Research Center.***************************************************** The Northern California Chapter of ACRP, Thursday Evening, Dec. 11, 2008

Speaker: David Vulcano, MSW, LCSW, MBA, CIP, assistant vice president for clinical research with Hospital Corporation of America in Nashville, Tenn Date and time:  December 11, 2008 (Thursday), 6:00 – 9:00 pm

6:00 – 6.45 PM   Registration, Networking, No Host Bar 6.45 – 7.30 PM   Dinner Buffet (chicken, vegetarian entrees) 7.30 -  8.00 PM  President’s Welcome, Year in Review                           2008 Volunteer Recognition                           2009 Board Elections                           Announcements 8.00 – 9.00 PM   David Vulcano, Chair, ACRP 2009 Board of Trustees

Location: the Stanford Grill, on the Stanford Golf Course, in Palo Alto, CaliforniaDirections: www.stanfordgrill.com Cost for Members: $ 5.00Cost for Non-members: $ 20.00RSVP Required for this Event (due to food order) via ACTEVA:https://www.acteva.com/go/nccacrp Speaker BioDavid Vulcano, MSW, LCSW, MBA, CIP joined the ACRP board in 2007.  He is assistant vice president for clinical research with Hospital Corporation of America in Nashville, Tenn., overseeing the research efforts of more than 170 hospitals, 105 surgery centers, various physician practices, and affiliated programs in 31 states, London, and Geneva.   He currently also serves as chair of ACRP’s Ethics & Public Policy Committee. ***************************************************** Monte Jade Science & Technology Association, Asian American Chapter (MJAA), Saturday Morning, Dec. 13, 2008

Topic: Comprehensive Job Hunting WorkshopInvited Speakers:Lee Rosenfield, Career Consultant at San Jose State UniversityAnne Broderick, Executive Coach and Career Management ConsultantDate and Time: Saturday, December 13, 2008 10:00-12:00 p.m.

12 5/25/2023

10:00 AM – Registration and Networking10:30 AM – Speaker Presentation11:30 AM – Q&ALocation: ITRI, Conference Room IE, 2880 Zanker Rd. Suite 109, San Jose, CA 95134Admission: RSVP by sending an email with your full name to mixer@mjaa.net • $5 for members• $10 for non-membersAt the door: • Add $5

***************************************************** Bio2Device Group, Tuesday Morning, Dec. 16, 2008

Topic: "Evidence-Based Medicine: What are the Expectations for New Products." Speaker: David L. Horwitz, M.D., Ph.D., Worldwide Vice President, Clinical Affairs and Evidence-Based Medicine, LifeScan, Inc.Date and Time: Tuesday, Dec. 16, 2008, 8:30 – 10:30 amLocation: Room 510, 505 W. Olive, Sunnyvale, CA (next to Sunnyvale Public Library)Cost: Free

Topic Description"Evidence Based Medicine" is a phrase we are hearing more frequently, and medical device and biotechnology companies are needing to incorporate this concept into their strategic thinking.  Evidenc- based medicine determines which products will gain market share and which will be reimbursed by third-party payers.  This talk will define the principles of evidence-based medicine and suggest how you can develop products and complete the clinical studies that will meet the evidence requirements. Speaker Bio Dr. David Horwitz is presently Vice President, WW Clinical Affairs & Evidence Based Medicine at LifeScan, Inc., a Johnson & Johnson company.  During his time at LifeScan, Dr. Horwitz has at various times been responsible for Clinical Research, Medical Affairs, Regulatory Affairs, and Advocacy & Professional Affairs.  Prior to coming to LifeScan, he served as Senior Vice President for Technology at Advanced Tissue Sciences in La Jolla, California, where he was responsible for basic research, process development, clinical research, regulatory affairs, and medical affairs, serving as a corporate officer and member of executive management team.  Prior to that he was Executive Vice President at SciClone Pharmaceuticals, and Vice President for Clinical and Professional Affairs at Baxter International.  He has had faculty positions in the medical schools at the University of Chicago and the University of Illinois, where he was clinical professor of medicine. Dr. Horwitz obtained his bachelor’s degree at Harvard University, majoring in Chemistry and Physics, and has an M.D. and Ph.D. (in physiology) from the University of Chicago and an MBA from the Lake Forest Graduate School of Management.  He is a Board-Certified internist and endocrinologist, and a Fellow of the American College of

13 5/25/2023

Physicians.  He has published over 100 articles in scientific and clinical journals, primarily in the areas of diabetes and metabolism.  He served as President of the Illinois Affiliate of the American Diabetes Association, and has also been active nationally in the ADA, acting as chair of the Committee on Planning and Organization, and vice-chair of the Committee on Research.  He is currently the industry representative on the Clinical Chemistry and Toxicology advisory panel of the U.S. Food and Drug Administration. ***************************************************** BioScience Forum, Wednesday Evening, Dec. 17, 2008

Topic: TBASpeaker: Mohan Iyer, Managing Director, Merchant Bank Burrill & CompanyDate and Time: Wednesday, Dec. 17, 2008; 6:00pm - 9:00pm6:00 PM - networking 7:00 PM - dinner 8:00 PM - presentationLocation: The Clarion Hotel, 401 East Millbrae Avenue, MillbraeFull info and Registration at:http://biosf.org/

Typical Cost: $50 before 11PM, Monday, Dec. 15th$60 on-site$30 full-time students pre-registration$35 full-time students on-site Acteva fees are added to the above prices Check website for latest information***************************************************** Bio2Device Group, Tuesday Morning, Jan. 6, 2008

Topic: “The Current Trends of China’s CRO Industry and the Keys to Success for a Chemistry Service Company”Speaker: Bruno Tse, Ph.D., M.B.A. (VP, Business Development, PepTech Corporation)Date and Time: Tuesday, January 6, 2009, 8:30 am to 10:30 amLocation: NOVA, 505 West Olive, Sunnyvale, Room 510Cost: Free

Topic Description:More and more pharmaceutical companies are outsourcing their R&D work to China. In this presentation, Bruno will discuss the current trends of China’s fast-growing CRO industry. Using PepTech Corporation as a case study, Bruno will further discuss the keys to success for a chemistry service company.

Speaker’s Bio:Bruno Tse currently serves as the Vice President of Business Development for PepTech Corporation, heading the business development efforts and corporate strategies of PepTech. Prior to this position, Bruno had played important roles in business development at several start-ups, including Amicus Therapeutics and Orphagen Pharmaceuticals. Bruno had also served as a Research Fellow at Merck where he completed a total synthesis of (-)-galbonolide B, a natural antifungal agent, by himself. He is a co-inventor of over ten issued patents, covering the discoveries of novel

14 5/25/2023

therapeutics in infectious diseases and cholesterol regulation. He earned his Ph.D. in chemistry at Harvard where he was awarded Robert Burns Woodward Prize, and holds an M.B.A. from the Wharton School of Business. He is also a registered patent agent and a four-time ironman triathlete.

15 5/25/2023